Study of Combination Therapy of Gliclazide MR and Basal Insulin Versus Insulin Monotherapy to Treat Type 2 Diabetes
Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
In recent years, with the further research of the pathogenesis of diabetes mellitus and the
mechanism of oral antidiabetes drugs, the early combination therapy of oral antidiabetes
drugs and insulin is getting paid more and more attention. A lot of studies have confirmed
that Gliclazide MRs have excellent reducing blood glucose efficacy and vascular protection.
Based on these theory and practice, this study is designed to demonstrate whether the
combination therapy of Gliclazide MR and basal insulin can control the blood glycemia
effectively and reduce the dosage of insulin and the hypoglycemia events compared to the
premix insulin monotherapy.